The global biosimulation market size was estimated at USD 1.20 billion in 2016. It is expected to expand at a noteworthy CAGR of 15.4% over the forecast period. Mounting cases of drug relapse due to acquired drug resistance in diseases such as cancer, tuberculosis, and other bacterial infections are among the key trends stimulating market growth.